Bristol Myers Squibb has expanded its software agreement with Schrödinger to deploy Bunsen, an AI platform built for molecular discovery workflows, across its research organization, with BMS scientists collaborating to develop new capabilities.
The deal builds on a November 2020 relationship in which BMS committed USD 55 million upfront and up to USD 2.7 billion in milestones for access to Schrödinger's physics-based platform.
No financial terms were disclosed for the new Bunsen agreement, though Schrödinger reported Q2 2026 annual contract value of USD 29.6 million, up 27%, with Bunsen's early access launch cited as a recent highlight.
What happened
Bristol Myers Squibb has expanded its existing software licensing agreement with Schrödinger to deploy Bunsen, an agentic AI platform designed for molecular discovery workflows, across its research organization. The agreement also covers Schrödinger's computational chemistry platform and RetroSynth, its retrosynthetic planning tool. BMS scientists will collaborate with Schrödinger to develop new Bunsen capabilities as part of the deal. No financial terms were disclosed.
Why it matters
This expands a relationship that began in November 2020, when BMS paid Schrödinger USD 55 million upfront with up to USD 2.7 billion in milestones tied to small molecule drug discovery. The move positions BMS to systematically automate multi-step molecular discovery workflows—planning, execution, and interpretation—using AI optimized for physics-based computational methods rather than general-purpose systems. Schrödinger reported Q2 2026 annual contract value of USD 29.6 million, representing 27% growth, with Bunsen's early access launch cited as a recent operational highlight.
What to watch
BMS is layering Bunsen on top of other AI infrastructure investments, including a July 2026 NVIDIA compute expansion and a May 2026 enterprise deployment of Anthropic's Claude across global operations. The collaboration model—where BMS scientists co-develop new Bunsen capabilities—differs from a pure software licensing transaction and may signal how enterprise AI deployments are structuring vendor partnerships in drug discovery.
Ask the AI about this article →
Bristol Myers Squibb's deployment of Bunsen represents a deepening commitment to AI-native drug discovery infrastructure that extends beyond standard enterprise software licensing. The November 2020 relationship—which involved substantial upfront capital and significant milestone payments (USD 55 million upfront, up to USD 2.7 billion in milestones)—demonstrated BMS's confidence in Schrödinger's physics-based computational approach. This new agreement shifts the relationship from purely transactional to collaborative, with BMS scientists co-developing new Bunsen capabilities alongside the platform deployment. This model reflects a broader trend in pharma AI partnerships where large enterprises are moving from vendor-consumer relationships toward joint innovation structures.
The timing of this expansion aligns with BMS's wider AI infrastructure buildout. In July 2026, BMS expanded its NVIDIA compute capacity, and in May 2026 deployed Anthropic's Claude across global operations. Bunsen's autonomous execution of multi-step molecular workflows—from planning through interpretation—complements these investments by creating a specialized, physics-informed layer atop general-purpose compute and reasoning capabilities. Schrödinger's Q2 2026 annual contract value of USD 29.6 million, up 27% year-over-year, with Bunsen's early access launch cited as an operational highlight, suggests the agentic platform is a material contributor to recent growth, though the broader BMS agreement's financial impact remains undisclosed.
For example, today's edition would include:
AI-summarized, only the topics you pick — one digest a day via Email, Slack, or Discord.
Free · takes 30 seconds · unsubscribe anytimeWhat is AIToday? →
Ask AI anything about this article. Q&As are published on this page for other readers too.
Analyst Ming-Chi Kuo says Nvidia has revived the Rubin CPX AI accelerator with a substantially redesigned arch…
A UK study by UK AI Security Institute and Limbic AI surveyed 6,474 British adults
Broadcom's Clayton Donley says companies are doing mission-critical work with AI agents quickly, but without t…
OpenAI released a new evaluation framework on July 17, 2026, urging companies to measure AI ROI by 'useful out…
As AI agents perform real business tasks, 'Agentic Identity' (giving each AI a unique employee-like ID) and 'D…
The European Union is expanding regulation of ChatGPT and will mandate protections for minors
